Hi, I'm Grace the new Marketing intern at Gladney. Recently I have been helping out with the organizing and researching for the Strategic Plan for the next two years. I have been graphing data and scouring through statistics in order to support Gladney's plan of action for the next couple of year.
However, through sitting all day in a cubicle by myself I have really enjoyed to opportunity to learn (as cliche as that sounds). One of the most interesting and disturbing facts I have recently discovered is the emergence of Ulipristal Acetate, or UPA, in the United States. UPA was created in Europe and has passed in 2009 with flying colors as the new emergency contraception for women. This new drug, named EllaOne by HRA Pharma, allows women 120 hours (5 days) for emergency contraception to take the pill after unprotected intercourse. Research has shown a decrease in the chance of pregnancy compared to the well-known Plan B in the United States and could possibly be distributed as an over-the-counter drug. Although the FDA has not approved EllaOne for US manufacturing, the advisory board for the FDA has passed the drug, signifying a positive approval for the drug in the near future. While this may sound like a new savior for confused teens not wanting a child, this new drug has potential to alter how many children are put up for adoption each year. In the eyes of Gladney and adoptive parents this drug is scary for the future generations of adoping children.
Today I went to a domestic adoption orientation. At the orientation I could see that these people going through the process of adoption are embarking on a selfless journey. It amazes me how complete strangers could gain my full respect with their attendance to learn about adoption with the hope of improving a child's life as well as their own.
I look forward to learning more about Gladney and the employees here because it is evident walking around how committed the employees are to making families happy.